Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of “Moderate Buy” from Analysts

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has earned a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $14.1667.

A number of equities analysts recently weighed in on FULC shares. Truist Financial set a $14.00 price objective on shares of Fulcrum Therapeutics in a research report on Monday, November 24th. Royal Bank Of Canada upped their price target on Fulcrum Therapeutics from $5.00 to $7.00 and gave the stock a “sector perform” rating in a research note on Thursday, October 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Wednesday, October 8th. HC Wainwright increased their target price on Fulcrum Therapeutics from $12.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, November 24th. Finally, Leerink Partners set a $20.00 target price on Fulcrum Therapeutics and gave the company an “outperform” rating in a report on Tuesday, October 21st.

Fulcrum Therapeutics Trading Down 3.3%

Shares of FULC opened at $8.76 on Friday. The company’s 50-day moving average price is $9.37 and its 200 day moving average price is $7.85. Fulcrum Therapeutics has a 12-month low of $2.32 and a 12-month high of $12.19. The firm has a market cap of $474.09 million, a P/E ratio of -7.42 and a beta of 3.17.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its earnings results on Wednesday, October 29th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.02). Equities research analysts forecast that Fulcrum Therapeutics will post -0.16 earnings per share for the current year.

Insider Activity at Fulcrum Therapeutics

In related news, Director Robert J. Gould sold 15,000 shares of Fulcrum Therapeutics stock in a transaction that occurred on Wednesday, November 19th. The shares were sold at an average price of $11.03, for a total value of $165,450.00. Following the completion of the transaction, the director owned 484,864 shares in the company, valued at approximately $5,348,049.92. The trade was a 3.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On Fulcrum Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Suvretta Capital Management LLC increased its position in shares of Fulcrum Therapeutics by 5.9% during the third quarter. Suvretta Capital Management LLC now owns 5,381,000 shares of the company’s stock worth $49,505,000 after acquiring an additional 298,100 shares during the period. Nantahala Capital Management LLC grew its stake in Fulcrum Therapeutics by 0.9% during the 1st quarter. Nantahala Capital Management LLC now owns 4,822,693 shares of the company’s stock worth $13,889,000 after purchasing an additional 42,985 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its stake in Fulcrum Therapeutics by 53.0% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,589,000 shares of the company’s stock worth $31,572,000 after purchasing an additional 1,589,000 shares in the last quarter. Balyasny Asset Management L.P. increased its holdings in Fulcrum Therapeutics by 8.4% during the 3rd quarter. Balyasny Asset Management L.P. now owns 1,450,480 shares of the company’s stock worth $13,344,000 after purchasing an additional 112,266 shares during the period. Finally, Exome Asset Management LLC raised its position in Fulcrum Therapeutics by 143.0% in the 1st quarter. Exome Asset Management LLC now owns 689,137 shares of the company’s stock valued at $1,985,000 after purchasing an additional 405,538 shares in the last quarter. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.